This editorial comments on two similar reviews of the literature on @entity0 and post-menopausal hormone therapies (HTs), puts the results in clinical perspective and suggests where they direct future research and clinical management. Although epidemiological studies have suggested increased @entity0 risk for all menopausal @entity101 regimens, unopposed oral @entity172 regimens have not been associated with any increased risk in recent randomized placebo controlled trials (RCTs). Added progestogen after 5 years of combined @entity101 in RCTs increases the risk of @entity0 by four cases per 10,000 per annum. As yet there is no evidence of different risk by progestogen type, dose or route. Theoretically local intrauterine progestogen may not give the same risk, but long-term trials are required. The commentary addresses the responsibility of the media in presenting levels of risk to the public, moving towards safer regimens, safer therapies, appropriate @entity1 choice and, in particular, correct timing of @entity101 where it is prescribed around menopause. This is in contrast to many of the trials when @entity101 was administered after the potential climacteric window of therapeutic opportunity. The current main indication for @entity101 remains for menopausal symptom control where it improves quality of life. @entity101 may be required for many years. The informed @entity1 should decide on @entity101 based on her personal benefits and risks, which should include all aspects of her health.

Current status of hormone therapy and XXXX .

@entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen'] @entity101 :: ('MESH:D006973', 'Disease') :: ['HT'] @entity1 :: ('9606', 'Species') :: ['woman', 'patient'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']
@entity0 :: (MESH:D001943,Disease) :: ['breast cancer']
